The clinical study to assess the efficacy, safety and pharmacokinetics of NS-304 in patients with pulmonary arterial hypertension (PAH)
Phase of Trial: Phase II
Latest Information Update: 11 Sep 2017
At a glance
- Drugs Selexipag (Primary)
- Indications Pulmonary arterial hypertension
- Focus Therapeutic Use
- Sponsors Actelion Pharmaceuticals; Nippon Shinyaku
- 08 Sep 2017 Status changed from active, no longer recruiting to completed.
- 18 Apr 2017 Primary endpoint (Change from baseline of pulmonary vascular resistance ) has been met,according to the results published in the Circulation Journal.
- 18 Apr 2017 Results published in the Circulation Journal